Hyperpolarized [1-13C] Pyruvate

Phase 2

UUniversity of Texas Southwestern Medical Center

Hyperpolarized [1-13C] Pyruvate is one of 14 therapeutic programs targeting Traumatic Brain Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Traumatic Brain InjuryEnrolling by invitation

High Risk Prostate CarcinomaActive, not recruiting

Traumatic Brain InjuryPhase 1

Enrolling by invitation

High Risk Prostate CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Traumatic Brain Injury

#DrugCompanyPhaseTrials

Namenda

AbbVie

Phase 2

1 2

Hyperbaric Oxygen Therapy

PPaul G. Harch, M.D.

Phase 2

2 3

Allorx

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

1 4

Hyperpolarized [1-13C] Pyruvate

UUniversity of Texas Southwestern Medical Center

Phase 2

1 5

Bont-a

SSir Run Run Shaw Hospital

Phase 2

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Hyperpolarized Pyruvate

SSunnybrook Health Sciences Centre

Phase 1

1 9

OVIDREL

OOrganon and Co

Phase 1

1 10

Sterile Saline

CClear Scientific, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Active, not recruiting

High Risk Prostate Carcinoma

NCT06384222

Q3 2034

Recruiting

Hepatocellular Carcinoma

NCT07807475

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy

Recruiting·AAbramson Cancer Center at Penn Medicine··NCT07807475·232 enrolled

High Risk Prostate Carcinoma1 trial

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients With High-Risk Prostate Cancer Receiving Neoadjuvant Therapy

Active, not recruiting·IIvan de Kouchkovsky, MD·Phase 2·NCT06384222·32 enrolled

Traumatic Brain Injury1 trial

Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate

Enrolling by invitation·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT03502967·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Hyperpolarized [1-13C] Pyruvate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hyperpolarized [1-13C] Pyruvate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity of Texas Southwestern Medical Center

Hyperpolarized [1-13C] Pyruvate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Q3 2034

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

High Risk Prostate Carcinoma1 trial

Traumatic Brain Injury1 trial

References

Drug Info

Quick Facts

Related News